Intercept Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Intercept Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Intercept Pharmaceuticals Inc Strategy Report
- Understand Intercept Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Intercept Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Intercept Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 10 Aug 2021 | Lorem |
| Intercept’s Ocaliva access in NASH likely to be choked by payers’ biopsy requirements; approval supported by efficacy but toxicity an uptake obstacle, experts say | 05 Dec 2019 | Reynald Castaneda |
| Intercept’s Phase II-ready Ocaliva/bezafibrate has mixed experts views on 2L vs 3L positioning in PBC; 25–30%-point boost over Ocaliva alone to show value | 19 Nov 2019 | Reynald Castaneda |
| Intercept’s Phase III Ocaliva trial in cirrhotic NASH to close enrollment at end of month; 739 patients randomized, 400 patients in screening stage, investigators say | 12 Nov 2019 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer